ImmunityBio, Inc. IBRX Total Liabilities & Equity
Total Liabilities & Equity at other companies
Other financials
Where this comes from
Reported directly by ImmunityBio, Inc. in its filing.
Tagged under the XBRL concept us-gaap:LiabilitiesAndStockholdersEquity.
The official record: ImmunityBio, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about ImmunityBio, Inc.'s total liabilities & equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is ImmunityBio, Inc.'s total liabilities & equity?
- ImmunityBio, Inc. (IBRX) reported total liabilities & equity of $646.64M in Q1 2026.
- How has ImmunityBio, Inc.'s total liabilities & equity changed year-over-year?
- ImmunityBio, Inc.'s total liabilities & equity increased by 112.9% year-over-year, from $303.76M to $646.64M.
- What is the long-term trend for ImmunityBio, Inc.'s total liabilities & equity?
- Over 5 years (2020 to 2025), ImmunityBio, Inc.'s total liabilities & equity has grown at a 17.8% compound annual growth rate (CAGR), from $221.38M to $501.9M.
- What does total liabilities & equity mean?
- Total assets = total liabilities + total equity. This must always balance — a fundamental accounting identity.